Table 4.
Assocation between CSM and BMI and covariates
| Variable | HR | 95% CI | p-value | |
|---|---|---|---|---|
| BMI, continuous(kg/m2) | 1.15 | 1.07–1.23 | <0.001 | |
| Gleason Score | ||||
| 7 vs 6 | 3.15 | 0.48–14.65 | 0.143 | |
| 8–10 vs 6 | 2.59 | 0.42–15.98 | 0.304 | |
| T-stage | ||||
| T2 vs T1c | 6.29 | 1.90–20.80 | 0.003 | |
| T3/4 vs T1c | 6.47 | 1.16–36.08 | 0.033 | |
| Log iPSA(ng/mL) | 2.41 | 1.29–4.50 | 0.006 | |
| Age(years) | 1.06 | 0.99–1.14 | 0.089 | |
| ADT Use(yes vs no) | 1.25 | 0.37–4.27 | 0.722 | |
DM, distant metastasis; CSM, cause-specific mortality; OM, overall mortality; BMI, body mass index; HR, hazard ratio; ADT, androgen deprivation therapy; iPSA, pre-treatment prostate specific antigen.